about
Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adultsUrine lateral flow lipoarabinomannan assay for diagnosing active tuberculosis in adults living with HIVThe impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort studyTime to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South AfricaDiscovery of dipiperidines as new antitubercular agents.Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppressionIdentification of SQ609 as a lead compound from a library of dipiperidines.High uptake of systematic HIV counseling and testing and TB symptom screening at a primary care clinic in South Africa.Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.Body mass index and risk of tuberculosis and death.A home tracing program for contacts of people with tuberculosis or HIV and patients lost to careEconomic challenges associated with tuberculosis diagnostic development.Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments.Ancient Disease, Modern Epidemiology: A Century of Progress in Understanding and Fighting Tuberculosis.The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis.Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a best-worst scaling survey.Active case finding for tuberculosis: what is the most informative measure for policy makers? [Correspondence]Urine antigen test for diagnosis of HIV-associated tuberculosisMaternal Motivation to Take Preventive Therapy in Antepartum and Postpartum Among HIV-Positive Pregnant Women in South Africa: A Choice ExperimentChest X-ray for tuberculosis preventive therapy: use cautionContact tracing versus facility-based screening for active TB case finding in rural South Africa: A pragmatic cluster-randomized trial (Kharitode TB)Health system barriers to implementation of TB preventive strategies in South African primary care facilitiesPerceptions of Community and Clinic-Based Adherence Clubs for Patients Stable on Antiretroviral Treatment: A Mixed Methods StudyCost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South AfricaThe impact of community- versus clinic-based adherence clubs on loss from care and viral suppression for antiretroviral therapy patients: Findings from a pragmatic randomized controlled trial in South AfricaFrom Epidemiologic Knowledge to Improved Health: A Vision for Translational Epidemiology
P50
Q24185754-669CB113-8B96-4899-83E4-AD3DA83CCA56Q24187533-DCEEFF16-5601-47AF-A4A5-276A1E597869Q28485439-AF158E91-2D9A-4D10-8237-C8671C81CBF5Q28533713-5667E2C6-4DC2-4D1F-9A9D-45C5945EA5FBQ30886962-FE1EB764-3A65-4F67-88CB-69212901D003Q33223601-38CE5E7D-B2E6-4375-81B0-C339DC00FD29Q33244525-1F62C3E2-D4BE-4702-8CDC-BFFF6C70983CQ33901601-77969313-E261-4B17-B5A7-8242753EAE01Q33977942-907CA05B-8747-43E7-82AA-5A9B971B3A5DQ34275768-A2FBA249-7ABE-4AD1-96D2-E429168305E3Q34383718-DC773EF3-FD6C-433E-A27D-013C82C362ABQ34713831-6753F56F-B511-463E-A9A3-E5D68B2AE802Q36122140-CD390681-BAC6-41CB-85CE-3B5EC23433C7Q36160928-1AC07D46-53B9-4077-A0A9-56305CBEE6DBQ37732922-47C444C1-784B-4495-AAFF-7B394D5EE0AFQ40006239-5A2861C7-D60D-4D47-893B-58F0C1A1DEB5Q53423263-1A516E22-02A6-48BB-944F-D4BF3D3A7552Q55518853-86548FBD-1717-4666-A401-7B2175C594E0Q57393049-9F89E984-3F3C-4AEF-A035-8CACC13FB98FQ57393053-57A0552F-6F6A-4C96-82F2-3EA1B39B6819Q58555011-BA645C81-A8B0-412D-80F5-0F54F6DD0B9BQ60343234-28435DFB-FAA8-4B94-8F2B-B64C1A4C1CE8Q64080147-5D516129-EA8B-4E7B-ADED-CFC2852FA075Q64243730-A11B40A4-CEFC-4398-A2A2-7C2C4F50A1A1Q90325666-52ED3142-C78D-4881-9A87-D38E3D1C5C68Q90868146-AEF50F22-54A6-40A2-A031-163CBB267A07Q92188321-92480086-77D8-4909-B699-50ADA52168DDQ92711395-A16E6B03-C4EF-499A-87AE-A77786A5F6D5
P50
description
researcher, ORCID id # 0000-0002-4544-4591
@en
wetenschapper
@nl
name
Colleen F Hanrahan
@ast
Colleen F Hanrahan
@en
Colleen F Hanrahan
@es
Colleen F Hanrahan
@nl
type
label
Colleen F Hanrahan
@ast
Colleen F Hanrahan
@en
Colleen F Hanrahan
@es
Colleen F Hanrahan
@nl
prefLabel
Colleen F Hanrahan
@ast
Colleen F Hanrahan
@en
Colleen F Hanrahan
@es
Colleen F Hanrahan
@nl
P106
P21
P31
P496
0000-0002-4544-4591